Table 2.
Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD)–related characteristics of the study population stratified by tertiles of serum osteoprotegerin
| Characteristic, Mean (±SD) or n (%) | Tertile 1 (1.21 to 5.03 pmol/L), n = 117 | Tertile 2 (5.05 to 7.45 pmol/L), n = 117 | Tertile 3 (7.46 to 22.31 pmol/L), n = 117 | Pa |
|---|---|---|---|---|
| Laboratory | ||||
| serum phosphate (mg/dl) | 3.4 (±0.55) | 3.5 (±0.64) | 3.6 (±0.57) | 0.05 |
| corrected serum calcium (mg/dl) | 9.2 (±0.39) | 9.1 (±0.46) | 9.2 (±0.43) | 0.54 |
| intact PTH ≥66 pg/ml | 33 (29.2) | 41 (36.6) | 40 (35.1) | 0.46 |
| intact PTH above KDOQI guideline | 27 (23.9) | 33 (29.5) | 34 (29.8) | 0.54 |
| bone-specific alkaline phosphatase (U/L)b | 28 (22, 36) | 29 (20, 40) | 27 (21, 35) | 0.18 |
| total alkaline phosphatase (U/L)b | 78 (68, 92) | 81 (65, 106) | 81 (68, 102) | 0.23 |
| Bone structure by pQCT | ||||
| cortical bone mineral content (g)c | 409.7 (±81.7) | 406.7 (±82.3) | 387.9 (±82.3) | 0.14 |
| Medications | ||||
| phosphorus binders | 9 (7.8) | 15 (13.0) | 19 (16.4) | 0.13 |
| active vitamin D sterols | 0 (0) | 4 (3.5) | 9 (7.8) | <0.01 |
PTH, parathyroid hormone; KDOQI, Kidney Disease Outcomes Quality Initiative; pQCT, peripheral quantitative computed tomography.
a
P value using ANOVA (continuous variables) or Pearson's chi-squared test (categorical variables).
b
Values presented as median (interquartile range). P-values calculated from log-transformed variable.
c
280 of 351 participants had cortical bone mineral content available.